教員紹介

畠山 浩人教授
Hiroto HATAKEYAMA

 現在、新たに承認される医薬品の大半は抗体など高分子医薬が占めています。また中分子に分類される核酸医薬やDDSを用いた核酸医薬、CAR-T細胞のような細胞の承認もここ数年で増加しています。従来とは異なる新たなモダリティが増えており、今後もますます開発が進んでいくと考えられています。
 畠山は北海道大学大学院薬学研究院在籍時はリポソームを用いた抗がん剤や核酸医薬のDDS開発研究に従事していました。MDアンダーソンがんセンター在籍時は金属ナノ粒子を用いた温熱療法や、トランスクリプトミクスやプロテオミクス情報を用いた生物学的な研究にも従事しました。千葉大学着任後は免疫チェックポイント阻害剤を中心に抗体医薬の薬効・動態・毒性の解析などの研究を進めています。
 多様な研究分野の経験を背景として畠山グループでは新たなモダリティを対象とし臨床の課題を見据えた研究を通じて理解を深め、このような分野の創薬の研究開発に強みを持つ学生を育てていきたいと考えています。研究室の特徴を生かし、実験で得られたデータを用いた統計や機械学習による解析、wetとdryの融合も進めています。
 欧米や日本以外のアジアにおいては研究を行う上で博士号は必須の資格になっています。創薬の研究開発もグローバル化しており、アカデミアに限らず日本国内の企業においても今後は博士号の必要性は高まると考えられます。これまでに畠山が筆頭著者として執筆した論文2報(Hatakeyama H, et al. Adv Drug Deliv Rev, 2011, Hatakeyama et al. Biol Pharm Bull, 2013)は、Pharmacology & Toxicology(薬理・毒性学)分野でTop1%の高被引用文献として世界的にも高く評価されています。世界で通用する研究を行うとともに、世界で活躍できる研究者の育成を目指して研究教育を進めていきたいと考えています。本研究室での研究内容に興味があれば遠慮なく連絡して下さい。

Profile

略歴

2003年 北海道大学薬学部総合薬学科卒業

2005年 北海道大学大学院薬学研究科修士課程修了

2008年 北海道大学大学院薬学研究科博士課程修了

2008年 北海道大学大学院薬学研究院 薬剤分子設計学研究室・助教

2009年 北海道大学大学院薬学研究院 未来創剤学研究室・特任助教

2013年 テキサス大学MDアンダーソンがんセンター婦人科腫瘍学講座・博士研究院

2016年 千葉大学大学院薬学研究院 臨床薬理学研究室・助教

2019年 千葉大学大学院薬学研究院 臨床薬理学研究室・准教授

2022年 千葉大学大学院薬学研究院 薬物学研究室・教授


授賞歴

2023年9月   令和5年度日本薬物動態学会奨励賞

2020年 5月        2020年度日本薬剤学会奨励賞

2019年 7月        医療薬学フォーラム2019/第27回クリニカルファーマシーシンポジウム 優秀ポスター賞

2018年 7月        KJYSP Chair’s Selection Award, The 2nd Workshop for Korea-Japan Young Scientists on Pharmaceutics

2017年 7月        第9回日本DDS学会奨励賞

2017年 3月        平成29年度日本薬学会奨励賞

2016年 12月      Outstanding Reviewer in International Journal of Pharmaceutics (Elsevier)

2016年 12月      Outstanding Reviewer in Colloids and Surfaces B: Biointerfaces (Elsevier)

2016年 12月      Outstanding Reviewer in Journal of Controlled Release (Elsevier)

2014年 11月      Outstanding Reviewer in Journal of Controlled Release (Elsevier)

2011年 1月        Top reviewer in Pharmaceutical Sciences 2010 (Elsevier)

2008年 7月        The Young Investigator Award, Liposome Research Days Conference 2008

2005年 5月        Travel Grant for Doctoral Course Students, Clark Memorial Foundation

2004年 5月        PSWC 2004 Student Travel grant


所属学会

日本薬学会、日本DDS学会(評議員)、日本薬剤学会(代議員)、日本薬物動態学会、日本癌学会、日本がん免疫学会、遺伝子デリバリー研究会、日本毒性学会(評議員)、アメリカ癌学会(AACR)


原著論文

  1. Hatakeyama H, Akita H, Maruyama K, Suhara T, Harashima H. Factor governing the in vivo tissue uptake of transferring coupled polyethylene glycol liposomes in vivo. Int. J. Pharm., 281: 25-33 (2004) 
  2. Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, Ueno M, Kobayashi H, Kikuchi H, Harashima H. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther., 14: 68-77 (2007)
  3. Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, Yasuda J,  Obata K, Kikuchi H, Ishida T, Kiwada H, Harashima H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm., 342: 194-200 (2007)
  4. Sakurai Y, Hatakeyama H, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. Efficient siRNA delivery to tumor cells using the combination of octaarginine, GALA and tumor-specific, cleavable PEG system. Biol. Pharm. Bull., 32(5): 928-932 (2009)
  5. Hatakeyama H, Ito E, Akita H, Oishi M, Nagasaki Y, Futaki S, Harashima H. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. J. Control. Release, 139(2): 127-132 (2009) 
  6. Sato Y, Hatakeyama H, Harashima H. Ornithine and tryptophan analogs as efficient polycations for siRNA delivery to tumor cells. Biol. Pharm. Bull., 33(7):1246-1249 (2010) 
  7. Takara K, Hatakeyama H, Ohga N, Hida K, Harashima H. Design of a dual-ligand system using a specific ligand and cell penetrating peptide, resulting in a synergistic effect on selectivity and cellular uptake. Int. J. Pharm., 396(1-2): 143-148 (2010)
  8. Hatakeyama H, Ito E, Yamamoto M, Akita H, Hayashi Y, Kajimoto K, Kaji N, Baba Y, Harashima H. A DNA microarray-based analysis of the host response to a non-viral gene carrier: a strategy for improving the immune response. Mol. Ther., 19(8): 1487-1498 (2011)
  9. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, Danev R, Nagayama K, Kaji N, Kikuchi H, Baba Y, Harashima H. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials, 32: 4306-4316 (2011)
  10. Kibria G, Hatakeyama H, Harashima H. A new peptide motif present in the protective antigen of anthrax toxin exerts its efficiency on the cellular uptake of liposomes and applications for a dual-ligand system. Int. J. Pharm., 412: 106-114 (2011)
  11. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J. Control. Release, 153: 141-148 (2011)
  12. Sakurai Y*, Hatakeyama H*, Sato Y, Akita H, Takayama K, Kobayashi S, Futaki S, Harashima H. Endosomal Escape and the Knockdown Efficiency of Liposomal-siRNA by the Fusogenic Peptide shGALA. Biomaterials, 32: 5733-5742 (2011) *Equally contributed
  13. Abe N, Abe H, Nagai C, Harada M, Hatakeyama H, Harashima H, Ohshiro T, Nishihara M, Furukawa K, Maeda M, Tsuneda S, Ito Y. Synthesis, structure, and biological activity of dumbbell-shaped nanocircular RNAs for RNA interference. Bioconjug. Chem., 19: 2082-2092 (2011) 
  14. Takahashi M, Nagai C, Hatakeyama H, Minakawa N, Harashima H, Matsuda A. Intracellular stability of 2’-OMe-4’-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic Acids Res., 40(12): 5787-5793 (2012).
  15. Takara K*, Hatakeyama H*, Kibria G, Ohga N, Hida K, Harashima H. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy. J. Control. Release, 161(1): 225-232 (2012). *Equally contributed
  16. Sato Y, Hatakeyama H, Sakurai Y, Hyodo M, Akita H, Harashima H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. J. Control. Release, 163: 267-276 (2012).
  17. Akita H, Ishiba R, Hatakeyama H, Tanaka H, Sato Y, Tange K, Arai M, Kubo K, Harashima H. A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like materials as a carrier for plasmid DNA. Adv. Healthc. Mater., 2(8): 1120-1125 (2013).
  18. Sakurai Y, Hatakeyama H, Sato Y, Hyodo M, Akita H, Harashima H. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Mol. Ther., 21(6): 1195-1203 (2013)
  19. Kibria G, Hatakeyama H, Ohga N, Hida K, Harashima H. The effect of liposomal size on the targeted delivery of doxorubicin to Integrin (alpha)v(beta)3-expressing tumor endothelial cells. Biomaterials, 34(22): 5617-5627 (2013)
  20. Kusumoto, K, Akita H, Ishitsuka T, Matsumoto Y, Nomoto T, Furukawa R, El-Sayed A, Hatakeyama H, Kajimoto K, Yamada Y, Kataoka K, Harashima H. A Lipid Envelop-type Nano Particle Incorporating a Multifunctional Peptide: GALA for the Systemic siRNA Delivery to the Pulmonary Endothelium. ACS Nano, 7(9): 7534-7541 (2013)
  21. Takahashi M, Yamada N, Hatakeyama H, Murata M, Sato Y, Minakawa N, Harashima H, Matsuda A. In vitro optimization of 2’-OMe-4’-thioribonucleoside modified anti-microRNA oligonucleotides (AMOs) and its targeting delivery to mouse liver using a liposomal nanoparticle. Nucleic Acids Res., 41(22): 10659-10667 (2013)
  22. Sakura Y, Hatakeyama H, Sato Y, Akita H, Ohga N, Hida K, Harashima H. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGDmodified liposomal-siRNA system. J. Control. Release, 173: 110-118 (2014)
  23. Hatakeyama H, Murata M, Sato Y, Takahashi M, Minakawa N, Matsuda A, Harashima H. The systemic administration of an anti-miRNA oligonucleotide encapsulated pH-sensitive liposome results in reduced level of hepatic microRNA-122 in mice. J. Control. Release, 173: 43-50 (2014)
  24. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat. Commun., 5, 3459 (2014)
  25. Tamaru M, Akita H, Kajimoto K, Sato Y, Hatakeyama H, Harashima H. An apolipoprotein E modified liposomal nanoparticle: Ligand dependent efficiency as a siRNA delivery carrier for mouse-derived brain endothelial cells. Int. J. Pharm., 465(1-2): 77-82 (2014)
  26. Hayashi Y, Suemitsu E, Kajimoto K, Sato Y, Akhter A, Sakurai Y, Hatakeyama H, Hyodo M, Kaji N, Baba Y, Harashima H. Hepatic Monoacylglycerol O-acyltransferase 1 as a Promising Therapeutic Target for Steatosis, Obesity, and Type 2 Diabetes. Mol. Ther. Nucleic Acids, 3:e154 (2014)
  27. Watanabe T*, Hatakeyama H*, Matsuda-Yasui C*, Sato Y*, Sudoh M, Takagi A, Hirata Y, Ohtsuki T, Arai M, Inoue K, Harashima H, Kohara M. In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. Sci. Rep., 4:4750 (2014) *Equally contributed
  28. Sakurai Y, Hatakeyama H, Akita H, Harashima H. Improvement of doxorubicin effect using liposomal anti-polo like kinase 1 siRNA in human renal cell carcinomas. Mol. Pharm., 11(8): 2713-2719 (2014)
  29. Ara MN, Matsuda T, Hyodo M, Sakurai Y, Hatakeyama H, Ohga N, Hida K, Harashima H. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells. Biomaterials, 35(25): 7110-7120 (2014)
  30. Tamaru M, Akita H, Nakatani T, Kajimoto K, Sato Y, Hatakeyama H, Harashima H. Application of apolipoprotein E modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid to the brain. Int. J. Nanomed., 9: 4267-4276 (2014)
  31. Kibria G, Hatakeyama H, Akiyama K, Hida K, Harashima H. Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump P-gp. Biol. Pharm. Bull., 37(12): 1926-1935 (2014)
  32. Akita H, Ishiba R, Togashi R, Tange K, Nakai Y, Hatakeyama H, Harashima H. A neutral lipid envelope-type nanoparticle composed of a pH-activated and vitamin E-scaffold lipid-like material as a platform for a gene carrier targeting renal cell carcinoma. J. Control. Release, 200: 97-105 (2015)
  33. Akita H, Noguchi Y, Hatakeyama H, Sato Y, Tange K, Nakai Y, Harashima H. Molecular tuning of a vitamin E-scaffold pH-sensitive and reductive cleavable lipid-like material for accelerated in vivo hepatic siRNA delivery. ACS Biomater. Sci. Eng., 1(9): 834-844 (2015)
  34. Matsui H, Sato Y, Hatakeyama H, Akita H, Harashima H. Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. Int. J. Pharm., 495(1): 171-178 (2015)
  35. Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, Hirata Y, Murakami S, Tanaka Y, Chayama K, Hatakeyama H, Hyodo M, Harashima H, Kohara M. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. J. Hepatol., 64(3):547-555 (2016)
  36. Hatakeyama H, Wu SY, Mangala LS, Lopez-Berestein G, Sood AK. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol. Biol., 1402:189-197 (2016).
  37. Sato Y, Hatakeyama H, Hyodo M, Harashima H. Relationship between the Physicochemical Properties of Lipid Nanoparticles and the Quality of siRNA Delivery to Liver Cells. Mol Ther., 24(4):788-95 (2016)
  38. Warashina S, Nakamura T, Sato Y, Fujiwara Y, Hyodo M, Hatakeyama H, Harashima H. A lipid nanoparticles for the efficient delivery of siRNA to dendritic cells. J. Control. Release, 225:183-191 (2016)
  39. Wu SY, Rupaimoole R, Shen S, Pradeep S, Pecot CV, Ivan C, Nagaraja AS, Gharpure KM, Pham E, Hatakeyama H, McGuire MH, Haemmerle M, Vidal-Anaya V, Olsen C, Rodriguez-Aguayo C, Filant J, Ehsanipour EA, Herbrich SM, Maiti SN, Huang L, Kim JH, Zhang X, Han H-D, Armaiz-Pena GN, Seviour EG, Tucker S, Zhang M, Yang D, Cooper LJ, Ali-Fehmi R, Bar-Eli M, Lee JS, Ram PT, Baggerly KA, Lopez-Berestein G, Hung MC, Sood AK. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nat. Commun., 7:11169 (2016).
  40. Kibria G, Hatakeyama H, Sato Y, Harashima H. Anti-Tumor Effect via Passive Anti-angiogenesis of PEGylated Liposomes Encapsulating Doxorubicin in Drug Resistant Tumors. Int. J. Pharm., 509(1-2):178-187 (2016)
  41. Huang Y, Lichtenberger LM, Taylor M, Bottsford-Miller JN, Haemmerle M, Wagner MJ, Lyons Y, Pradeep S, Hu W, Previs RA, Hansen JM, Fang D, Domiak PL, Filant J, Dial EJ, Shen F, Hatakeyama H, Sood AK. Anti-tumor and Anti-angiogenic Effects of Aspirin-PC in Ovarian Cancer. Mol. Cancer Ther., 15(12):2894-2904 (2016)
  42. Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huan Q, Court KA, Liu T, Nie S, Rodríguez-Aguayo C, Shen F, Huang Y, Hisamatsu T, Mitamura T, Shim J, Dorniak PL, Lingegowda MS, Petrillo M, Petyuk VA, Schepmoes AA, Shukla AK, Torres-Lugo M, Lee JS, Rodland KD, Fagotti A, López-Berestein G, Li C, Sood AK. Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. Cell Rep., 17(6):1621-1631 (2016)
  43. Court KA, Hatakeyama H, Wu SY, Lingegowda MS, Rodríguez-Aguayo C, López-Berestein G, Lee JS, Rinaldi C, Juan EJ, Sood AK, Torres-Lugo M. HSP70 inhibition synergistically enhances the effects of magnetic fluid hyperthermia in ovarian cancer. Mol. Cancer Ther., 16(5):966-976 (2017)
  44. Ando H, Hatakeyama H, Sato H, Hisaka A, Suzuki H. Determinants of intestinal availability for P-glycoprotein substrate drugs estimated by extensive simulation with mathematical absorption models. J. Pharm. Sci., 106(9): 2771-2779 (2017)
  45. Mitamura T, Pradeep S, McGuire M, Wu SY, Hatakeyama H, Ma S, Chen X, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, and Sood AK. Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein, prostate-associated. Oncogene, 37(6): 722-731 (2018) 
  46. Hatakeyama H (Corresponding Author), Fujiwara T, Sato H, Terui A, Hisaka A. Investigation of metabolomic changes in sunitinib-resistant human renal carcinoma 786-O cells by capillary electrophoresis-time of flight mass spectrometry. Biol. Pharm. Bull., 41(4); 619-627 (2018)
  47. Yoshioka H, Sato H, Hatakeyama H, Hisaka A. Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients, Blood Adv., 2(10): 1066-1075 (2018)
  48. Sato H, Uzu M, Kashiba T, Fujiwara T, Hatakeyama H, Koichi U, Hisaka A. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity. Eur. J. Pharmacol., 847: 143-157 (2019) 
  49. Kurino T, Matsuda R, Terui A, Suzuki H, Kokubo T, Uehara T, Arano Y, Hisaka A, Hatakeyama H (Corresponding Author). Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models. J. ImmunoTher. Cancer, 8: e000400 (2020)
  50. Cao Q, Zhou M, Wang W, Shi S, Zhao J, Geng Ku, Huang Q, Wen X, Li F,  Hatakeyama H, Xu C, Piwnica-Worms D, Peng W, Zhou D, Sood AK, Li C. Induction of Anti-tumor Immunity in Mice by the Combination of Nanoparticle-Based Photothermolysis and Anti-PD-1 Checkpoint Inhibition. Nanomedicine, 25: 102169 (2020)
  51. Tomizawa S, Tomari M, Tanaka A, Utsumi N, Sato H, Hatakeyama H, Hisaka A, Kohama T, Yamagata K, Honda T, Nakamura H, Murayama T. Inhibitory effects of ceramide kinase on Rac1 activation, lamellipodium formation, cell migration, and metastasis of A549 lung cancer cells. Biochim. Biophys. Acta - Molecular and Cell Biology of Lipids, 1965(6): 158675 (2020)
  52. Hisaka A, Yoshioka H, Hatakeyama H, Sato H, Onouchi Y, Anzai N. Global comparison of changes in the number of test-positive cases and deaths by coronavirus infection (COVID-19) in the world. J. Clinical. Med., 9(6): 1904 (2020)
  53. Cho R, Sakurai Y, Jones HS, Akita H, Hisaka A, Hatakeyama H (Corresponding Author). Silencing of VEGFR2 by RGD modified lipid nanoparticle synergistically enhanced the efficacy of anti-PD-1 antibody by accelerating vascular normalization and infiltration of T cells in tumors. Cancers, 12, 3630 (2020)
  54. Kanamori T, Miyazaki N, Aoki S, Ito K, Hisaka A, Hatakeyama H (Corresponding Author). Investigation of energy metabolic dynamism in hyperthermia-resistant ovarian and uterine cancer cells under heat stress. Sci. Rep., 14726 (2021)
  55. Okawa T, Hara K, Goto M, Kiukuchi M, Kogane M, Hatakeyama H, Tanaka H, Shirane D, Akita H, Hisaka A, Sato H. Effect of cGAMP emitted from metastatic brain tumors on the metabolism of astrocytes in contact with tumors. Int. J. Mol. Sci., 22, 9028 (2021)
  56. Maishi N, Sakurai Y, Hatakeyama H, Umeyama Y, Nakamura T, Endo R, Alam MT, Li C, Annan DA, Kikuchi H, Morimoto H, Morimoto M, Akiyama K, Ohga N, Hida Y, Harashima H, Hida K. Novel antiangiogenic therapy targeting biglycan in tumor endothelial cells using liposomal-siRNA delivery system. Frontiers Cell and Developmental Biology, Cancer Sci., 113(5), 1855-1867 (2022)
  57. Nakamura T, Kawakami K, Nomura M, Sato Y, Hyodo M, Hatakeyama H, Hayakawa Y, Harashima H. Combined nano cancer immunotherapy based on immune status in a tumor microenvironment. J. Control. Release, 345, 200-213 (2022)
  58. Tanaka A, Honda T, Yasue M, Yamazaki R, Hatakeyama H, Hisaka A, Mashimo M, Kohama T, Nakamura H, Murayama T. Effects of ceramide kinase knockout on lipopolysaccharide-treated sepsis-model mice: Changes in serum cytokine/chemokine levels and increased lethality. J. Pharmacol. Sci., 150(1), 1-8 (2022)
  59. Yamamoto M*, Kurino* T, Matsuda R*, Jones HS, Nakamura Y, Tsuji AB, Sugyo A, Tsuda R, Matsumoto Y, Sakurai Y, Suzuki H, Sano M, Osada K, Uehara T, Ishii Y, Akita H, Arano Y, Hisaka H, Hatakeyama H (Corresponding Author). Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect, J. Control. Release, 352, 328-337 (2022) *Equally contributed
  60. Arai T*, Kokubo T*, Tang R, Abo H, Terui A, Hirakawa J, Akita H, Kawashima H, Hisaka A, Hatakeyama H (Corresponding Author). Tumor associated neutrophils and macrophages exacerbate anti-drug IgG mediated anaphylactic reaction against an immune checkpoint inhibitor, J. ImmunoTher. Cancer, 10:e005657 (2022) *Equally contributed
  61. Gomi M, Sakurai Y, Sato M, Tanaka H, Miyatake Y, Fujiwara K, Watanabe M, Shuto S, Nakai Y, Tange K, Hatakeyama H, Akita H. Delivering mRNA to Secondary Lymphoid Tissues by Phosphatidylserine-loaded Lipid Nanoparticles. Adv. Healthc. Mater., in press
  62. Doi M, Tanaka H, Ohoto T, Miura N, Sakurai Y, Hatakeyama H, Akita H. Reactivation of anti-cancer immunity by resetting inter-organ crosstalk of immune-suppressive cells with nano-particulated anti-inflammatory drug. Small, in press